Company: CRVO
Filing Date: 2025-05-12
Form Type: 424B5
Source: 0001437749-25-016167
Chunk: 7

Company: CervoMed Inc.
Filing Date: 2025-05-12
Form: 424B5
Chunk 7
---
ation of Certain Documents by Reference” on page S-15 of this prospectus supplement.

Corporate History and Information

We are a Delaware corporation that was incorporated in June 2015 and previously was named “Diffusion Pharmaceuticals Inc.” Prior to June 2015, we were a Nevada corporation. On August 16, 2023, we completed a merger transaction with EIP Pharma, Inc., a Delaware corporation, and changed our name to “CervoMed Inc.”

We maintain our principal executive offices at 20 Park Plaza, Suite 424, Boston, Massachusetts 02216.

Our telephone number there is (617) 744-4400. The address of our website is www.cervomed.com. The information set forth on, or connected to, our website is expressly not incorporated by reference into, and does not constitute a part of, this prospectus supplement.

We are a “smaller reporting company” as defined in Rule 12b-2 of the Exchange Act, and have elected to take advantage of certain of the scaled disclosure available for smaller reporting companies in this prospectus supplement as well as our filings under the Exchange Act.

Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge through the investor relations page of our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.

<div align='center'>S-4</div>

THE OFFERING

| Common stock offered by us:              | Shares of our common stock having an aggregate offering price of up to $50,000,000.                                                                                                                                                                                                                                                                             |
| Shares of common stock to be outstanding 
 immediately after this offering:         | Up to 14,592,000 shares, assuming sales of 5,889,281 shares of common stock are made in this offering at an offering price of $8.49 per share, which was the last reported sale price of shares of our common stock on The NASDAQ Capital Market on May 9, 2024. The actual number of shares issued will vary depending on the sales price under this offering. |
| Plan of Distribution:                    | “At the market offering” that may be made from time to time through or to our sales agent, Leerink Partners, as agent. See “Plan of Distribution” on page S-14